Página principal > Artículos > Resultados de la búsqueda: Leukaemia

Artículos

  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Artículos Encontrados 24 registros  anterior11 - 20siguiente  ir al registro: La búsqueda tardó 0.02 segundos. 
11.
12 p, 1.1 MB The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants / Rio-Machin, Ana (Queen Mary University of London) ; Vulliamy, Tom (Queen Mary University of London) ; Hug, Nele (University of Edinburgh) ; Walne, Amanda (Queen Mary University of London) ; Tawana, Kiran (Addenbrookes Hospital (Cambridge, Regne Unit)) ; Cardoso, Shirleny (Queen Mary University of London) ; Ellison, Alicia (Queen Mary University of London) ; Pontikos, Nikolas (Queen Mary University of London) ; Wang, Jun (Queen Mary University of London) ; Tummala, Hemanth (Queen Mary University of London) ; Al Seraihi, Ahad Fahad H. (Queen Mary University of London) ; Alnajar, Jenna (Queen Mary University of London) ; Bewicke-Copley, Findlay (Queen Mary University of London) ; Armes, Hannah (Queen Mary University of London) ; Barnett, Michael (University of British Columbia) ; Bloor, Adrian (Christie Hospital) ; Bödör, Csaba (Semmelweis University) ; Bowen, David (St James's University Hospital) ; Fenaux, Pierre (Université Paris) ; Green, Andrew (Our Lady's Children's Hospital) ; Hallahan, Andrew (Queensland Children's Hospital (Austràlia)) ; Hjorth-Hansen, Henrik (St Norwegian University of Science and Technology) ; Hossain, Upal (Barts NHS Trust) ; Killick, Sally (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ; Lawson, Sarah (Birmingham Children's Hospital) ; Layton, Mark (Hammersmith Hospital (Londres)) ; Male, Alison M. (Great Ormond Street Hospital for Children (Londres)) ; Marsh, Judith (King's College Hospital NHS Foundation Trust) ; Mehta, Priyanka (University Hospitals Bristol NHS Foundation Trust) ; Mous, Rogier (Universitair Medisch Centrum Utrecht) ; Nomdedeu, Josep (Institut d'Investigació Biomèdica Sant Pau) ; Owen, Carolyn (Foothills Medical Centre) ; Pavlu, Jiri (Hammersmith Hospital (Londres)) ; Payne, Elspeth M. (University College London) ; Protheroe, Rachel E. (University Hospitals Bristol NHS Foundation Trust) ; Preudhomme, Claude (Universitaire de Lille. Jean-Pierre Aubert Research Center) ; Pujol-Moix, Nuria (Institut d'Investigació Biomèdica Sant Pau) ; Renneville, Aline (Broad Institute of MIT and Harvard) ; Russell, Nigel (Nottingham University Hospitals NHS Trust (Regne Unit)) ; Saggar, Anand (St George's Hospital Medical School) ; Sciuccati, Gabriela (Hospital de Pediatría "Prof. Dr. Juan P. Garrahan") ; Taussig, David (Royal Marsden Hospital (Regne Unit)) ; Toze, Cynthia L. (University of British Columbia) ; Uyttebroeck, Anne (University Hospitals Leuven (Bèlgica)) ; Vandenberghe, Peter (University Hospitals Leuven (Bèlgica)) ; Schlegelberger, Brigitte (Medizinische Hochschule Hannover) ; Ripperger, Tim (Medizinische Hochschule Hannover) ; Steinemann, Doris (Medizinische Hochschule Hannover) ; Wu, John (British Columbia Children's Hospital (Vancouver, Canadà)) ; Mason, Joanne (Birmingham Women's NHS Foundation Trust) ; Page, Paula (Birmingham Women's NHS Foundation Trust) ; Akiki, Susanna (Qatar Rehabilitation Institute) ; Reay, Kim (Birmingham Women's NHS Foundation Trust) ; Cavenagh, Jamie D. (Barts NHS Trust) ; Plagnol, Vincent (University College London) ; Caceres, Javier F. (University of Edinburgh) ; Fitzgibbon, Jude (Queen Mary University of London) ; Dokal, Inderjeet (Barts Health NHS Trust) ; Universitat Autònoma de Barcelona
The inclusion of familial myeloid malignancies as a separate disease entity in the revised WHO classification has renewed efforts to improve the recognition and management of this group of at risk individuals. [...]
2020 - 10.1038/s41467-020-14829-5
Nature communications, Vol. 11 (february 2020)  
Registro completo - Creative Commons
12.
1 p, 257.6 KB Publisher Correction : Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study / Kayser, Sabine (Heidelberg University Hospital (Alemanya)) ; Rahmé, Ramy (Université Paris Diderot. Hôpital Saint Louis) ; Martínez-Cuadrón, David (Centro de Investigación Biomédica en Red de Cáncer) ; Ghiaur, Gabriel (Johns Hopkins University) ; Thomas, Xavier (Centre Hospitalier Lyon-Sud) ; Guerci-Bresler, Agnes (Nancy University Hospital) ; Garrido, Ana (Institut d'Investigació Biomèdica Sant Pau) ; Pigneux, Arnaud (Bordeaux University Hospital (França)) ; Gil, Cristina (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Raffoux, Emmanuel (Université Paris Diderot) ; Tormo, Mar (Universitat de València) ; Vey, Norbert (Institut Paoli Calmette) ; de la Serna, Javier (Hospital Universitario 12 de Octubre (Madrid)) ; Salamero, Olga (Hospital Universitari Vall d'Hebron) ; Lengfelder, Eva (University Hospital Mannheim (Alemanya)) ; Levis, Mark (Johns Hopkins University) ; Fenaux, Pierre (Université Paris Diderot) ; Sanz, Miguel A.. (Centro de Investigación Biomédica en Red de Cáncer) ; Platzbecker, Uwe (University Hospital Leipzig. Medical Clinic and Policlinic I, Hematology and Cellular Therapy) ; Schlenk, Richard F. (NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center and Heidelberg University Hospital) ; Adès, Lionel (Université Paris Diderot) ; Montesinos, Pau (Centro de Investigación Biomédica en Red de Cáncer) ; Universitat Autònoma de Barcelona
2021 - 10.1038/s41375-021-01358-3
Leukemia, Vol. 35 (november 2021) , p. 3631  
Registro completo - Creative Commons
13.
9 p, 621.5 KB Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study / Kayser, Sabine (Heidelberg University Hospital (Alemanya)) ; Rahmé, Ramy (Université Paris Diderot) ; Martínez-Cuadrón, David (Centro de Investigación Biomédica en Red de Cáncer) ; Ghiaur, Gabriel (Johns Hopkins University) ; Thomas, Xavier (Centre Hospitalier Lyon-Sud. Hospices Civils de Lyon) ; Sobas, Marta (Wroclaw Medical University) ; Guerci-Bresler, Agnes (Nancy University Hospital) ; Garrido, Ana (Institut d'Investigació Biomèdica Sant Pau) ; Pigneux, Arnaud (Bordeaux University Hospital (França)) ; Gil, Cristina (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Raffoux, Emmanuel (Université Paris Diderot. Hôpital Saint Louis) ; Tormo, Mar (Hospital Clínic Universitari (València)) ; Vey, Norbert (Institut Paoli Calmette) ; de la Serna, Javier (Hospital Universitario 12 de Octubre (Madrid)) ; Salamero, Olga (Hospital Universitari Vall d'Hebron) ; Lengfelder, Eva (University Hospital Mannheim (Alemanya)) ; Levis, Mark (Johns Hopkins University) ; Fenaux, Pierre (Université Paris Diderot. Hôpital Saint Louis) ; Sanz, Miguel A.. (Centro de Investigación Biomédica en Red de Cáncer) ; Platzbecker, Uwe (University Hospital Leipzig) ; Schlenk, Richard F. (German Cancer Research Center and Heidelberg University Hospital) ; Adès, Lionel (Université Paris Diderot) ; Montesinos, Pau (Centro de Investigación Biomédica en Red de Cáncer) ; Universitat Autònoma de Barcelona
Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73. [...]
2020 - 10.1038/s41375-020-0758-4
Leukemia, Vol. 34 (february 2020) , p. 2333-2341  
Registro completo - Creative Commons
14.
10 p, 1.3 MB Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission : analysis from CALGB 10403 and the CIBMTR / Wieduwilt, Matthew J. (University of California) ; Stock, Wendy (University of Chicago Medicine) ; Advani, Anjali (Cleveland Clinic) ; Luger, Selina (University of Pennsylvania Medical Center) ; Larson, Richard A. (University of Chicago Medicine) ; Tallman, Martin (Memorial Sloan Kettering Cancer Center. Leukemia Service, Department of Medicine) ; Appelbaum, Frederick (Fred Hutchinson Cancer Research Center) ; Zhang, Mei-Jie (Medical College of Wisconsin. Division of Biostatistics) ; Bo-Subait, Khalid (Medical College of Wisconsin) ; Wang, Hai-Lin (Medical College of Wisconsin) ; Bhatt, Vijaya Raj (University of Nebraska Medical Center) ; Dholaria, Bhagirathbhai (Vanderbilt University Medical Center) ; Eapen, Mary (Medical College of Wisconsin) ; Hamadani, Mehdi (Medical College of Wisconsin) ; Jamy, Omer (University of Alabama at Birmingham) ; Prestidge, Tim (Starship Children's Hospital (Auckland, Nova Zelanda)) ; Pulsipher, Michael (Children's Hospital Los Angeles Cancer) ; Ritchie, David (Peter MacCallum Cancer Centre) ; Rizzieri, David (Duke University) ; Sharma, Akshay (St. Jude Children's Research Hospital (Memphis, Estats Units d'Amèrica)) ; Barba, Pere (Hospital Universitari Vall d'Hebron) ; Sandmaier, Brenda M. (Fred Hutchinson Cancer Research Center) ; de Lima, Marcos (University Hospitals Case Medical Center) ; Kebriaei, Partow (The University of Texas MD Anderson Cancer Center) ; Litzow, Mark (Mayo Clinic.) ; Saber, Wael (Medical College of Wisconsin) ; Weisdorf, Daniel (University of Minnesota) ; Universitat Autònoma de Barcelona
Optimal post-remission therapy for adolescents and young adults (AYAs) with Ph-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is not established. We compared overall survival (OS), disease-free survival (DFS), relapse, and non-relapse mortality (NRM) for patients receiving post-remission therapy on CALGB 10403 to a cohort undergoing myeloablative (MA) allogeneic hematopoietic cell transplantation (HCT) in CR1. [...]
2021 - 10.1038/s41375-021-01213-5
Leukemia, Vol. 35 (march 2021) , p. 2076-2085  
Registro completo - Creative Commons
15.
36 p, 6.5 MB CD133-directed CAR T-cells for MLL leukemia : on-target, off-tumor myeloablative toxicity / Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zanetti, S. R. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Baroni, Matteo Libero. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Sánchez-Martínez, D. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Molina, Oscar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Closa, A. (Universitat Pompeu Fabra) ; Agraz-Doblás, Antonio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Marín, P. (Hospital Clínic i Provincial de Barcelona) ; Eyras, Eduardo (Institució Catalana de Recerca i Estudis Avançats) ; Varela, Ignacio (Universidad de Cantabria. Departamento de Biología Molecular) ; Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
2019 - 10.1038/s41375-019-0418-8
Leukemia, Vol. 33 Núm. 8 (january 2019) , p. 2090-2125  
Registro completo - Creative Commons
16.
13 p, 3.4 MB NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia / López-Millán, Belén (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Sanchéz-Martínez, Diego (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Roca Ho, Heleia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Molina, Oscar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Díaz de la Guardia, Rafael (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Torres, Raul (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Fuster, José Luis (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia)) ; Ballerini, Paola (Pediatric Hematology. Armand Trousseau Hospital) ; Suessbier, U. (University Hospital Zurich (Suïssa)) ; Nombela-Arrieta, Cesar (University Hospital Zurich (Suïssa)) ; Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
B cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with cure rates of ∼80%. MLL-rearranged (MLLr) B-ALL (MLLr-B-ALL) has, however, an unfavorable prognosis with common therapy refractoriness and early relapse, and therefore new therapeutic targets are needed for relapsed/refractory MLLr-B-ALL. [...]
2019 - 10.1038/s41375-018-0353-0
Leukemia, Vol. 33 Núm. 7 (january 2019) , p. 1557-1569  
Registro completo - Creative Commons
17.
6 p, 605.0 KB Histamine receptor 1 is expressed in leukaemic cells and affects differentiation sensitivity / Cornet-Masana, Josep Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Banús, Antònia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Cuesta-Casanovas, Laia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Carbó, José María (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Guijarro, F. (Hospital Clínic i Provincial de Barcelona) ; Torrente, M. Á. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Esteve Reyner, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Risueño, Ruth M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Despite the success of immunotherapy in several haematological neoplasms, the effectiveness in acute myeloid leukaemia (AML) is still controversial, partially due to the lack of knowledge regarding immune-related processes in this disease and similar neoplasias. [...]
2020 - 10.1111/jcmm.15930
Journal of Cellular and Molecular Medicine, Vol. 24 Núm. 22 (november 2020) , p. 13536-13541  
Registro completo - Creative Commons
18.
5 p, 786.3 KB B-cell leukemia transdifferentiation to macrophage involves reconfiguration of DNA methylation for long-range regulation / Bueno-Costa, Alberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Piñeyro, David (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Soler, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Javierre, B. M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Raurell Vila, Helena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Subirana-Granés, Marc (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pasquali, Lorenzo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Martinez-Climent, J. A. (Centro de Investigación Biomédica en Red de Cáncer) ; Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
2020 - 10.1038/s41375-019-0643-1
Leukemia, Vol. 34 Núm. 4 (april 2020) , p. 1158-1162  
Registro completo - Creative Commons
19.
17 p, 2.3 MB H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells / Godfrey, L. (University of Oxford. Department of Medicine) ; Crump, N. T. (University of Oxford. Department of Medicine) ; O'Byrne, Sorcha (Department of Paediatrics. University of Oxford) ; Lau, I. J. (University of Oxford. Department of Medicine) ; Rice, S. (University of Oxford. Department of Medicine) ; Harman, J. R. (University of Oxford. Department of Medicine) ; Jackson, T. (Department of Paediatrics. University of Oxford) ; Elliott, N. (Department of Paediatrics. University of Oxford) ; Buck, G. (Department of Paediatrics. University of Oxford) ; Connor, C. (Great Ormond Street Hospital for Children (Londres)) ; Thorne, R. (University of Oxford. Department of Medicine) ; Knapp, D. J. H. F. (MRC Weatherall Institute of Molecular Medicine. Radcliffe Department of Medicine. University of Oxford) ; Heidenreich, O. (Newcastle University. Wolfson Childhood Cancer Research Centre) ; Vyas, P. (Department of Haematology. Oxford University Hospitals NHS Foundation Trust) ; Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Inglott, S. (Great Ormond Street Hospital for Children (Londres)) ; Ancliff, P. (Great Ormond Street Hospital for Children (Londres)) ; Geng, H. (Department of Laboratory Medicine. University of California. San Francisco) ; Roberts, I. (Department of Paediatrics. University of Oxford) ; Roy, A. (Department of Paediatrics. University of Oxford) ; Milne, T. A. (University of Oxford. Department of Medicine) ; Universitat Autònoma de Barcelona
MLL gene rearrangements (MLLr) are a common cause of aggressive, incurable acute lymphoblastic leukemias (ALL) in infants and children, most of which originate in utero. The most common MLLr produces an MLL-AF4 fusion protein. [...]
2021 - 10.1038/s41375-020-0808-y
Leukemia, Vol. 35 Núm. 1 (january 2021) , p. 90-106  
Registro completo - Creative Commons
20.
12 p, 1.8 MB Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study / Burger, Jan A. (University of Texas MD Anderson Cancer Center. Department of Leukemia) ; Barr, Paul M. (Wilmot Cancer Institute, University of Rochester Medical Center) ; Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital) ; Owen, Carolyn (University of Calgary. Tom Baker Cancer Centre) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ; Bairey, Osnat (Tel Aviv University. Rabin Medical Center, Petah Tikva, Israel and Sackler Faculty of Medicine) ; Hillmen, Peter (University of Leeds. The Leeds Teaching Hospitals, St. James Institute of Oncology) ; Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Center) ; Devereux, Stephen (NHS Foundation Trust. Kings College Hospital) ; Grosicki, Sebastian (Silesiam Medical University. Department of Hematology and Cancer Prevention) ; McCarthy, Helen (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ; Simpson, David (North Shore Hospital) ; Offner, Fritz (Universitair Ziekenhuis Gent) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Dai, Sandra (Pharmacyclics LLC, an AbbVie Company) ; Lal, Indu (Pharmacyclics LLC, an AbbVie Company) ; Dean, James P. (Pharmacyclics LLC, an AbbVie Company) ; Kipps, Thomas J. (UCSD Moores Cancer Center) ; Universitat Autònoma de Barcelona
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0. [...]
2019 - 10.1038/s41375-019-0602-x
Leukemia, Vol. 34 (october 2019) , p. 787-798  
Registro completo - Creative Commons

Artículos : Encontrados 24 registros   anterior11 - 20siguiente  ir al registro:
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos